Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

WCLC 2024 Insights: Optimal Management of Malignant Pleural Effusion

Insights from 2024 WCLC

P. Lee

Year in Review 2024 - NSCLC Perioperative Therapy

Oncology 2024 Year in Review

B. Halmos

Role of Surgery in Locally Advanced NSCLC

Memorial Sloan Kettering Cancer Center

K. Gray

Neoadjuvant vs. Adjuvant: A New Paradigm for NSCLC

Total Health

D. Carbone

ESMO 2024 Summary: Key Trial Insights on Managing NSCLC With Low PD-…

ecancer

L. Paz-Ares

The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

IO Advances in Metastatic NSCLC Treatment

Fox Chase Cancer Center

H. Borghaei

EGFRm Lung Cancer: Overview & Treatment Sequence

GRACE

J. Rotow

Metastatic EGFRm NSCLC: 1L Therapy Options

University of Colorado Cancer Center

T. Patil

Lazertinib in 1L EGFR-Mutant NSCLC: Unique Mechanism and Benefits of…

Mariam Alexander

Surveillance Imaging in Solid Tumors: More Complicated Than It Appea…

ecancer

C. Booth

Unresectable Stage 3 NSCLC: Patient Selection and Treatment Options

Fox Chase Cancer Center

C. Aggarwal

Year in Review 2024 - Targeted Therapy for NSCLC

Nebraska Oncology Society

J. Murray

WCLC 2024 Review: MARIPOSA Trial - Extended Follow Up and Patient Re…

ecancer

E. Felip

Surgical Advances in Lung Cancer

University of Colorado Department of Medicine

S. Randhawa

Imaging of Precision Therapy in Lung Cancer

International Cancer Imaging Society (ICIS)

M. Nishino

Current Landscape of Neoadjuvant, Perioperative, and Adjuvant IO in …

UCLA Health

J. Lee

Multidisciplinary Panel Discussion: New Treatment Options for Surgic…

David Carbone

B. Stiles

The Efficacy of Immunotherapies for EGFRm Lung Cancer

GRACE

I. Dagogo-Jack, J. Rotow, M. Shields, A. Cooper, A. Qin